Cancer Genetics Inc. (NASDAQ: CGIX) open the trading on February 12, 2021, with a bit cautious approach as it glided -4.55% to $6.72. During the day, the stock rose to $7.03 and sunk to $6.6213 before settling in for the price of $7.04 at the close. Taking a more long-term approach, CGIX posted a 52-week range of $1.92-$17.50.
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -6.50%. Meanwhile, its Annual Earning per share during the time was 41.70%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 22.70%. This publicly-traded company’s shares outstanding now amounts to $6.84 million, simultaneously with a float of $3.73 million. The organization now has a market capitalization sitting at $28.83 million. At the time of writing, stock’s 50-day Moving Average stood at $3.56, while the 200-day Moving Average is $3.44.
Let’s gauge the efficiency of the firm, which has a total of 110 employees. It has generated 66,409 per worker during the last fiscal year. Meanwhile, its income per employee was -62,591. The stock had 1.89 Receivables turnover and 0.29 Total Asset turnover. For the Profitability, stocks gross margin was +49.34, operating margin was -37.14 and Pretax Margin of -101.26.
Cancer Genetics Inc. (CGIX) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Cancer Genetics Inc.’s current insider ownership accounts for 7.49%, in contrast to 18.60% institutional ownership.
Cancer Genetics Inc. (CGIX) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 12/30/2018 suggests? It has posted -$4.2 earnings per share (EPS) beating the forecaster’s viewpoint (set at -$4.8) by $0.6. This company achieved a net margin of -94.25 while generating a return on equity of -97.06. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
Cancer Genetics Inc.’s EPS increase for this current 12-month fiscal period is 22.70%. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 40.00% through the next 5 years, which can be compared against the 41.70% growth it accomplished over the previous five years trading on the market.
Cancer Genetics Inc. (NASDAQ: CGIX) Trading Performance Indicators
Let’s observe the current performance indicators for Cancer Genetics Inc. (CGIX). It’s Quick Ratio in the last reported quarter now stands at 0.60. The Stock has managed to achieve an average true range (ATR) of 1.44. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 4.58.
In the same vein, CGIX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.85.
Technical Analysis of Cancer Genetics Inc. (CGIX)
[Cancer Genetics Inc., CGIX] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 28.14% While, its Average True Range was 1.79.
Raw Stochastic average of Cancer Genetics Inc. (CGIX) in the period of the previous 100 days is set at 29.97%, which indicates a major rise in contrast to 23.05% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 277.46% that was higher than 181.15% volatility it exhibited in the past 100-days period.